Trials / Completed
CompletedNCT00815906
Study Evaluating Single Doses Of SBI-087 In Japanese Subjects With Rheumatoid Arthritis
An Ascending Single Dose Study Of The Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of SBI-087 Administered To Japanese Subjects With Rheumatoid Arthritis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 20 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and tolerability of single doses of SBI-087 in Japanese subjects with rheumatoid arthritis.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SBI-087 | IV, Single dose |
| DRUG | SBI-087 | IV, Single dose |
| DRUG | SBI-087 | SC, Single dose |
| DRUG | SBI-087 | SC, Single dose |
Timeline
- Start date
- 2008-12-01
- Primary completion
- 2012-04-01
- Completion
- 2012-05-01
- First posted
- 2008-12-31
- Last updated
- 2024-08-14
Locations
7 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00815906. Inclusion in this directory is not an endorsement.